drugset / Trial / NCT03014804
Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma
Phase 2
Withdrawn
Jonsson Comprehensive Cancer Center
Brain Tumor Funders Collaborative · collabBristol-Myers Squibb · collabNorthwest Biotherapeutics · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This phase II trial studies the side effects of autologous dendritic cells pulsed with tumor lysate antigen vaccine and nivolumab and to see how well they work in treating patients with glioblastoma that has come back. Vaccines made from a person's tumor cells may help the body build an effective immune response to kill tumor cells. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread. Giving dendritic cell-autologous lung tumor vaccine and nivolumab may work better in treating patients with glioblastoma.
Timeline
- Start
- 2019-12-01
- Primary completion
- 2020-12-01
- Completion
- 2022-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DCVax-L | Vaccine | — | Other |
| Subject | Nivolumab | Monoclonal antibody | — | Intravenous |